Cellectis S.A. holds a "Moderate Buy" rating with a price target of $6.33, despite recent EPS misses. Institutional investment, especially from UBS, has risen to 63.9%. The biotech firm focuses on gene-edited therapies and anticipates an EPS of -0.46.

NodeGuardian

2026-04-21 06:05:23

Abstract generation in progress

Analysts have given Cellectis S.A. (NASDAQ:CLLS) a consensus “Moderate Buy” rating, with an average 12-month price target of $6.33, despite the company missing recent EPS expectations. Institutional investors, notably UBS, have significantly increased their stakes, bringing their total ownership to approximately 63.9%. The biotechnology company, specializing in gene-edited cell therapies, saw its shares open at $3.36 and anticipates an EPS of -0.46 for the current fiscal year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
304.6K Popularity
#
Gate13thAnniversaryLive
764.61K Popularity
#
BitcoinBouncesBack
175.26K Popularity
#
USIranTalksProgress
881.17K Popularity
#
HKUnveilsNewCryptoRules
275.62K Popularity

Sitemap

Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin